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ACE Inhibition and Cardiovascular
Mortality and Morbidity in Essential
Hypertension: The End of the Search
or a Need for Further Investigations?
Luis M. Ruilope, Antonio Coca, Massimo Volpe, and Bernard Waeber
Scientific evidence currently available supports the con-
cept that renin-angiotensin blockade with angiotensin con-
verting enzyme inhibitors as a first-line treatment exhibits
in arterial hypertension beneficial effects in the prevention
of mortality and morbidity comparable to those achieved
with diuretics and -blockers. In addition, the renin-an-
giotensin blockade has also proved to be beneficial in the
secondary prevention of several complications of hyper-
tensive disease such as after myocardial infarction and
congestive heart failure, as well as in the prevention of the
incidence of type 2 diabetes, and the progression of dia-
betic and nondiabetic nephropathy. In this later regard,
recent evidence with angiotensin II receptor antagonists
in reducing the progression of nephropathy in type 2
diabetes strongly confirms that antagonism of the renin-
angiotensin system is an effective approach to cardiovas-
cular and renal disease. Finally, the renin-angiotensin
blockade in high-risk patients may reduce cardiovascular
mortality independently of the effect on blood pressure
(BP). The effect of other antihypertensive drugs on car-
diovascular risk in patients with high-normal BP should be
investigated to establish whether they exhibit a compara-
ble effect or whether there is a class-related benefit
of drugs blocking the renin-angiotensin system. Such a
strategy could also be encouraged to design future inter-
ventional studies with the newer classes of compounds
(angiotensin II AT1-receptor antagonists, vasopeptidase
inhibitors, endothelin antagonists), which would have
the additional potential advantage of providing informa-
tion more easily transferable to large-scale clinical
practice. Am J Hypertens 2002;15:367–371 © 2002
American Journal of Hypertension, Ltd.
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T he goal of antihypertensive treatment is to reducecardiovascular mortality and morbidity associatedwith arterial hypertension by using a strategy fo-
cused both on lowering blood pressure (BP) and minimiz-
ing the impact of other associated cardiovascular risk
factors. This strategy has the aim of avoiding or delaying
fatal and nonfatal cardiovascular events and prolonging
life in hypertensive patients.1,2 Prospective randomized
intervention trials, in which active therapy was compared
to placebo, have demonstrated that even modest reductions
of 5 to 6 mm Hg in diastolic BP and of 10 to 12 mm Hg
in systolic BP over a 5-year period are associated with a
35% to 42% decreased risk of stroke and a 12% to 16%
decreased risk of coronary heart disease.3–5 In those trials
a high proportion of patients received combination therapy
with two or more drugs rather than a single diuretic or a
-blocker agent. Thus, the conclusion to be drawn from
those initial studies was that the reduction of cardiovas-
cular events and death observed in hypertensive patients
was related to the magnitude of the BP decrease attained
by treatment, and not to the specific properties of a par-
ticular class of antihypertensive agents.6
Angiotensin Converting Enzyme
Inhibition: Good Expectations
The work of John Laragh’s group, recently reviewed by
this journal,7–9 introduced the concept of blockade of the
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renin-angiotensin system for the control of BP. About 70%
of the hypertensive population (those with normal and
elevated values of plasma renin) would respond to the
administration of a drug capable of blocking the effects of
angiotensin II. Further investigation by the same group
advanced the possibility that global cardiovascular risk
was associated in an independent manner with renin pro-
file in hypertension.10 This theory was also valid in dif-
ferent animal models.11–13 Blockade of the system was
obtained initially through the administration of proprano-
lol, which decreased renin secretion by the kidney. An-
giotensin converting enzyme (ACE) inhibitors came to fill
the need of blockade of the system in daily clinical prac-
tice, and angiotensin receptor blockers have been recently
added to the armamentarium at our disposal to counteract
the effects of angiotensin II.
Since the introduction of ACE inhibitors for the treat-
ment of hypertension at the beginning of the 1980s, these
drugs have been widely used in clinical practice to treat all
stages of essential hypertension. In many countries ACE
inhibitors are the drugs most commonly used, either as
monotherapy or in association with other antihypertensive
drugs.14,15 For many years their clinical use was based on
their efficacy (not different from others classes), better
tolerability, and easy combination, in particular with a
diuretic. Beyond these properties, the demonstration of
beneficial effects on intermediate end points such as the
regression of left ventricular hypertrophy16,17 or their ca-
pacity to diminish proteinuria18 became available and con-
tributed to the increase in prescriptions for ACE inhibitors
for hypertension. It was inferred from these salutary ef-
fects and other observations on target organ damage that
probably ACE inhibitors could be more effective than
other antihypertensive drugs in the prevention of cardio-
vascular morbidity and mortality in arterial hypertension.
To further support this potential positive effect, evidence
emerged later convincingly demonstrating the beneficial
effects of ACE inhibitors in the secondary prevention of
mortality after acute myocardial infarction,19–22 conges-
tive heart failure,23–25 as well as in diabetic and nondia-
betic nephropathy.26–28 The excellent results of these stud-
ies on secondary prevention seemed to herald that renin-
angiotensin system blockade with ACE inhibitors would
provide additional cardiovascular benefits beyond BP con-
trol in essential hypertensive patients. Therefore, one
would expect ACE inhibitors to be superior to conven-
tional therapy for primary prevention of cardiovascular
events associated with elevated BP.
ACE Inhibitor Trials
in Hypertension:
Surprise and Disappointment?
However, the results of the first available studies address-
ing this hypothesis, which mostly compared ACE inhibi-
tor-based strategies with diuretic-based or -blocker-
based strategies, such as the United Kingdom Prospective
Diabetes Study (UKPDS),29,30 Captopril Prevention
Project (CAPPP),31 and Swedish Trial in Old Patients with
hypertension-2 (STOP-2)32 studies have failed so far to
demonstrate the postulated higher potential of ACE inhib-
itors for primary prevention of cardiovascular mortality
and morbidity. In fact, these studies showed comparable
efficacy of ACE inhibitors to conventional therapeutic
strategies for most end points. With an optimistic attitude,
one may conclude that treatment of hypertension with
ACE inhibitors is at least as good as conventional therapy
in the reduction of fatal and nonfatal cardiovascular
events, while, at the same time, they display an overall
better tolerability. Some data from these studies indicate
that ACE inhibitors improve the prognosis in diabetics. In
this direction are the trend for less myocardial infarctions
in UKPDS,29,30 and the positive effect of this therapy on
the prevalence of this event and heart failure in the group
of diabetic patients included in the CAPPP31 study. How-
ever, one should pragmatically conclude, in agreement
with the Blood Pressure-Lowering Treatment Trialist Col-
laboration,33 that ACE inhibitors do not provide further
benefit than that related to the BP lowering effect, as
attained with diuretics or -blockers.
However, important questions remain unanswered:
have we thoroughly explored the capacity in ACE inhib-
itors for primary and secondary prevention of cardiovas-
cular events and death in hypertension? For sure, these
compounds are recommended as first-line drugs in hyper-
tension, but shall we prefer them to the other first-line
classes of antihypertensive drugs simply based on their
beneficial effects in other cardiovascular and renal diseases
and their better tolerability?
Limitations of Study
Design Testing ACE Inhibitors
Cardiovascular disease is the most common cause of death
in Western countries34,35 and arterial hypertension is a
major predisposing factor for this outcome. The risk at-
tributable to BP is the highest in patients with severe
hypertension (systolic BP 180 mm Hg or diastolic BP
110 mm Hg), but fortunately, only a minority of the
hypertensive population falls in this category. The popu-
lation with elevated BP may be represented as a risk
pyramid, with the greatest number of people at the base
(relative risk augmented but not high) and the smallest
number at the top (where relative risk is high or very high).
Therefore, the largest absolute number of complications
and the highest excess of deaths attributable to high BP
occurs at the base of the pyramid34–36 in subjects with
high-to-normal (systolic BP 130 to 139 mm Hg or dia-
stolic BP 85 to 89 mm Hg) or mild hypertension (systolic
BP 140 to 149 mm Hg or diastolic BP 90 to 99 mm Hg).
These considerations highlight the necessity of reducing
BP below these values to achieve substantial reductions in
complications in the community as a whole.1,2
The expected differences among antihypertensive drug
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classes, provided they exist, are probably difficult to detect
in studies performed on patients with baseline BP values
in the highest range (where BP reduction per se is the most
important factor lowering risk and mortality). Table 1
contains the data of initial and final BP levels in most of
the recently published studies. As can be seen the decrease
in BP was very high in most studies. On the contrary, if BP
independent effects are relevant, it is mostly in studies
including individuals with BP levels within the lower
ranges (mild or high-to-normal BP), where the differences
can be detected. In this respect, the average initial BP
values in the group of 758 hypertensive patients with type
2 diabetes included in the UKPDS study29,30 were 159/94
mm Hg for those randomized to captopril and 159/93 mm
Hg for patients included in the atenolol group. After 9
years of follow-up, the final average BP values were
144/83 and 143/81 mm Hg, respectively, with average BP
reductions of about 15 mm Hg for systolic BP and 10 mm
Hg for diastolic BP. Despite the magnitude of the BP
reduction, the majority of patients in this study remained
in the initial grade or stage 1 (mild hypertension) due to
the insufficient reduction of SBP achieved with either
drug, and no differences between treatments were ob-
served (RR  1.10; P  not significant). However, a
significant reduction of 32% (P  .019) in mortality was
observed in patients with tight control (final BP 144/82
mm Hg) when compared to the group of patients with less
tight control (final BP 154/87 mm Hg). The results were
similar in the other two major studies in which ACE
inhibitors were compared to conventional therapy, the
CAPPP31 and the STOP-232 studies. In these two studies
final BP values, in particular those of the systolic compo-
nent remained above the expected goal (140 mm Hg) in
more than 50% of patients. Could this fact have influenced
the final results? It has to be considered here that the
primary end point in most of these studies consist of a
composite target including myocardial infarction, stroke,
and cardiovascular death. Interestingly, recent reports
have described that in treated hypertensives one-third of
strokes can be ascribed to the insufficient control of
BP,37,38 and the accompanying elevated risk.35 In fact, the
different BP control was, according to the researchers the
explanation for the higher prevalence of stroke in patients
treated with captopril as compared to those receiving con-
ventional therapy in the CAPPP study.31 The possibility
that differences in systolic BP control accounted for a
different prevalence of stroke in several previously pub-
lished studies has been recently confirmed in the recent
analysis performed by Staessen et al.39 The relevance of
attaining a good BP, even in the presence of an ACE
inhibitor, has been recently stressed by the results of the
Perindopril Protection Against Recurrent Stroke Study
(PROGRESS).40 This study has investigated the capacity
of perindopril alone or in association with indapamide, as
compared to placebo, in the secondary prevention of
stroke. The prevention of a second stroke was significantly
lower when both drugs were given together and BP de-
creased by mean 12/5 mm Hg for systolic and diastolic
BP, respectively. Perindopril alone lowered BP by 5/3 mm
Hg and no prevention of stroke was observed.
It seems then reasonable to speculate that the excess of
risk related to uncontrolled BP may substantially contrib-
ute to offset the possible different influence of the various
classes of drugs on outcomes. All these parameters (BP
values before intervention, magnitude of the BP reduction,
final BP values achieved by antihypertensive treatment)
may affect the reduction in morbidity and mortality ob-
served and suggest that the results obtained with these
different strategies and antihypertensive drugs is largely
dependent on the BP reduction and independent of the
specific drug treatment. This conclusion highlights the
major problems inherent to these studies designed to dis-
sect any possible additional and drug-related beneficial
effect beyond BP lowering, and implies that different de-
sign strategies should be undertaken for this purpose. In
favor of this possibility are also the recently published
results of studies in which calcium channel blockers
(CCB) were compared to conventional therapy. The IN-
SIGHT41 and the NORDIL42 studies have in fact con-
firmed what had been observed in the STOP-2 study; on
the basis of the levels of BP and risk at baseline, and the
level of BP attained with therapy during a short follow-up
(3 to 5 years), therapy with CCB does not seem to differ
from conventional therapy.
Good News and HOPE
Recently the data of the Heart Outcomes Prevention Eval-
uation study (HOPE) and Microalbuminuria, Cardiovas-
cular and Renal Outcomes in the Heart Outcomes Pre-
vention Evaluation (MICROHOPE) studies have been
published.43,44 In a sample of 9500 patients with high
cardiovascular risk (53% normotensive, 39% diabetics)
Table 1. Initial, final, and BP decrease in recently
published studies
Studies
Initial
BP
Final
BP
BP
Decrease
UKPDS 159/94 144/82 15/12
HOT, DBP 90 mm Hg 170/105 144/85 26/20
HOT, DBP 80 mm Hg 170/105 140/81 30/24
STOP-2, DIU/BB 194/98 158/81 36/17
STOP-2, ACEI 194/98 159/81 35/17
STOP-2, CCB 194/98 159/80 35/18
INSIGHT, DIU 176/99 138/82 38/17
INSIGHT, CCB 176/99 138/82 38/17
NORDIL, DIU/BB 173/105 151/88 22/17
NORDIL, CCB 173/105 154/88 19/17
BP  blood pressure; UKPDS  United Kingdom Prospective Diabe-
tes Study; HOT  Hypertension Optimal Treatment; DBP  diastolic
blood pressure; STOP-2  Swedish Trial in Old Patients with hyper-
tension-2; DIU/BB  diuretic/beta-blocker; ACEI  angiotensin
converting enzyme inhibitor; CCB  calcium channel blockers;
INSIGHT  International Nifedipine GITS study: Intervention as a
Goal in Hypertension Treatment; NORDIL  NORdic DILtiazem
study.
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treated with a high dose (10 mg) of the ACE inhibitor
ramipril during 4 years, a 22% (P  .01) reduction in
mortality and morbidity was obtained with the ACE in-
hibitor with respect to placebo. Initial average BP values
were 139/79 mm Hg (high-to-normal BP) and thus it has
been claimed that the results of this study cannot be
extrapolated to hypertension. In fact, the investigators
described that only 50% of patients presented a previous
history of high BP.39 However, the fact that three-quarters
of patients were receiving, at baseline, one or several
drugs capable of lowering BP and more importantly the
new threshold BP (130/85 mm Hg) for patients in the
conditions considered by entry criteria in these two studies
confirm that nowadays most patients entering these studies
require actually a strict (130/85 mm Hg) BP control.1,2
Patients randomized to placebo in the HOPE study did not
modify systolic BP values, whereas a decrease of 2 mm
Hg was observed in diastolic BP. Meanwhile, in patients
receiving ramipril both systolic BP and diastolic BP were
reduced by 3 mm Hg. This allows the consideration that
within the range of high-to-normal BP patients with high
cardiovascular risk, may benefit from treatment with ACE
inhibitors even if this is associated with very small BP
reductions. The clinical advantage of such a therapy was
even more independent of BP changes in diabetics,44 in
whom the decrease was negligible. The HOPE and MI-
CROHOPE studies support the guidelines of the JNC-VI
and WHO-ISH guidelines,1,2 which suggest that in high
risk patients antihypertensive treatment must be started in
the high-to-normal range of BP with the aim of achieving
BP values 130/85 mm Hg, or even lower than 125/75
mm Hg in the presence of renal failure. However, a
discrepancy exists among the data of HOPE43 and
PROGRESS.40 In the last study and unlike a more marked
decrease in BP, no prevention of stroke was seen when the
ACE inhibitor was administered alone.
Another interesting finding observed both in CAPPP31
and HOPE43 studies was the potential capacity of ACE
inhibitors to prevent the development of type 2 diabetes. In
this regard, most recent evidence in patients with type 2
diabetes and nephropathy indicate that inhibition of the
renin-angiotensin system by AT1 receptor antagonists
markedly reduces development of overt diabetic nephrop-
athy and retards the progression of renal failure once the
nephropathy is present, and these effects are independent
of changes in BP.45–47 Altogether these observations em-
phasize the need for further studies in which the capacity
of different classes of antihypertensive drugs to reduce
cardiovascular events and death is analyzed looking at
subjects with baseline BP lower than in previous trials.
Table 2 summarizes the desirable characteristics of future
studies. This may allow to dissect specific effects of drug
classes on cardiovascular risk in the absence of the con-
founding effect of a relevant BP reduction that may offset
the potential BP-independent benefits of specific drug
classes.
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